Valuation
- Market cap
- 248,970,000
- Revenue TTM
- $0
- Net income TTM
- $-1,445,603
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 186,623
- Avg volume
- —
- Day's range
- $15.61 – $17.82
- Shares out
- 14,855,000
- Stochastic %K
- 24%
- Beta
- —
- Analysts
- Sell
- Price target
- $48.50
Company profile
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United Sta...
Show more
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 919 659 5677
- Website
- https://vogenx.com
- Address
- 3901 Barrett Drive, Suite 300, Raleigh, United States
